Is there any truth in the myth that IVF treatments involve weight gain?
COH
IVF
antagonist protocol
weight change
weight gain
Journal
Frontiers in reproductive health
ISSN: 2673-3153
Titre abrégé: Front Reprod Health
Pays: Switzerland
ID NLM: 9918230899006676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
10
2023
accepted:
14
12
2023
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
To examine body weight change in women undergoing A prospective cohort study among IVF patients treated between 2018 and 2019. Each patient underwent weight measurement three times during the treatment cycle: before treatment, at the beginning of the hormonal stimulation, and at the completion of the cycle, on the day of the pregnancy test. Data were also analyzed according to the body mass index (BMI) groups for normal weight, overweight, and obese patients. Finally, weight changes were recorded following altogether 519 treatment cycles, 240, 131, and 148 cycles, for normal weight, overweight, and obese patients, respectively. The change in the patient's weight was clinically non-significant either during the waiting period or during gonadotropin administration, and overall, during the first, second, or third treatment cycles. The recorded mean total weight change of 0.26 ± 1.85, 0.4 ± 1.81, and 0.17 ± 1.7, after the first, second, or third treatment cycles, represent a change of 0.36%, 0.56%, and 0.23% of their initial weights, respectively. This change of less than 1% of the body weight falls short of the clinically significant weight gain of 5%-7%. Analyzing the data for the various BMI groups, the changes observed in body weight were under 1%, hence with no clinical significance. The findings of the study reject the myth that hormone therapy involves clinically significant weight gain, and this can lower the concerns of many patients who are candidates for treatment of assisted reproductive technology.
Identifiants
pubmed: 38260051
doi: 10.3389/frph.2023.1327110
pmc: PMC10800931
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1327110Informations de copyright
© 2024 Saar-Ryss, Shilo, Friger, Grin, Michailov, Meltcer, Zaks, Rabinson, Lazer and Friedler.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.